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Summary Neuroblastoma is the most common extracranial solid tumour of childhood. Amplification of the
proto-oncogene, N-myc, confers a poor prognosis in neuroblastoma, while hyperdiploidy is associated with a
favourable outcome. Little is known about the contribution of tumour-suppressor genes to the development or
progression of neuroblastoma. We examined allelic imbalance at the locus of the tumour-suppressor gene, APC
(adenomatous polyposis coli), on chromosome 5q using a polymerase chain reaction (PCR)-based assay. Nine
of 24 (37.5%) informative neuroblastoma tumours showed allelic imbalance (Al) at this locus. Clinical data
concerning N-myc amplification and DNA content were correlated with these results in the same patients.
Allelic imbalance was found only in tumours containing a single copy of the N-myc gene and exhibiting
hyperdiploidy. All nine patients with Al of chromosome 5q were alive after a median follow-up period of 46
months, while 7 of 15 (47%) of those lacking Al at this locus had died (P=0.018). Allelic imbalance at three
additional loci on chromosome 5 was demonstrated in tumours that exhibited Al at the APC locus, suggesting
that endoreduplication of chromosome 5 had occurred. Fluorescent in situ hybridisation (FISH) analysis of
tumour tissue from one patient exhibiting AI demonstrated two, three, four or six copies of the APC gene per
cell, consistent with this hypothesis. These data suggest that allelic imbalance of chromosome 5 is involved in at
least a subset of neuroblastomas and influences survival in patients with neuroblastoma.
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Neuroblastoma is the most common extracranial solid
tumour of childhood. It originates from primitive neural
crest cells that form the sympathetic nervous sysem. Several
clinical features of neuroblastoma suggest that discrete
biological subgroups of this malignancy exist. Infants less
than one year of age generally have a favourable response to
therapy, and spontaneous regression is sometimes seen
(Evans et al., 1976; MacMillan et al., 1976; Brodeur and
Castleberry, 1993). Conversely, other neuroblastomas behave
aggressively, often resulting in death despite surgery, high-
dose chemoradiotherapy and autologous bone marrow
transplantation. Determination of the molecular basis for
these disparate clinical outcomes could improve our under-
standing of neuroblastoma and be valuable in planning
therapy.
Several cytogenetic and molecular alterations have been
described in neuroblastoma. In 1983, Schwab et al.
determined that a gene termed N-myc, related to the proto-
oncogene c-myc, was amplified in many human neuroblasto-
ma cell lines (Schwab et al., 1983). Subsequent studies have
shown that DNA amplification of this gene, found in about
25% of neuroblastomas, is associated with rapid progression
of disease (Seeger et al., 1985; Look et al., 1991; Fong et al.,
1992). In one study of neuroblastoma, DNA content, which
grossly reflects chromosome number, was diploid (DNA
index=1) in 44%, near-diploid (DNA index 1.18) in 6%,
near-triploid (DNA index= 1.25- 1.68) in 48% and hypote-
traploid (DNA index= 1.85) in 2% of 59 neuroblastoma
tumours analysed (Bourhis et al., 1991). In infants,
hyperdiploidy is associated with a favourable outcome.
Conversely, diploidy rarely occurs in localised disease, and
it predicts a poor outcome in disseminated disease of infants
(Look et al., 1984, 1991).
No known tumour-suppressor genes have yet been directly
associated with neuroblastoma, but published data suggest
that tumour-suppressor gene loci may be important in this
cancer. Loss of heterozygosity (LOH) has been demonstrated
at chromosome Ip in 25%, at llq in 42% and at 14q in 23%
of neuroblastomas, while LOH was seen in only 5% of
neuroblastomas following extensive studies of other loci
(Brodeur et al., 1977; Suzuki et al., 1989; Srivatsan et al.,
1991; Fong et al., 1992). Putative tumour-suppressor genes at
lp, llq and 14q have not been identified. LOH at lp is
associated with a poor outcome in neuroblastoma, which
may be caused at least in part by the observation that LOH
of lp frequently occurs in tumours with N-myc amplification
(Fong et al., 1989, 1992). It has been reported that the
neurofibromatosis type I protein, which has tumour-
suppressive properties, was absent in four of ten neuroblas-
toma cell lines (The et al., 1993).
A number of tumour-suppressor genes have now been
identified in other types of cancer. The most frequently
affected tumour-suppressor gene is p53. LOH of 17p, the
locus of the p53 gene, was not seen in neuroblastoma
(Imamura et al., 1993; Komuro et al., 1993; Vogan et al.,
1993). Another tumour-suppressor gene that has been
associated with a variety of cancer types is APC
(adenomatous polyposis coli), located on chromosome 5q21.
This gene is responsible for the hereditary syndrome, familial
adenomatous polyposis (Herrera et al., 1986; Groden et al.,
1991; Joslyn et al., 1991; Kinzler et al., 1991; Nishisho et al.,
1991), and is involved by heterozygous deletion or mutation
in sporadic colorectal cancers (Miyoshi et al., 1992; Powell et
al., 1992), gastric carcinomas (Horii et al., 1992a; Nakatsuru
et al., 1992), pancreatic cancers (Horii et al., 1992b),
oesophageal cancers (Boynton et al., 1992) and in small-cell
lung cancers (Ashton-Rickardt et al., 1991; D'Amico et al.,
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1992). Because of the widespread involvement of the APC
locus in a variety of cancers, we examined this genetic locus
for allelic imbalance in neuroblastoma.
Materials and methods
Patient samples
Paired normal and tumour DNA samples were obtained from
the Pediatric Oncology Group (POG) Neuroblastoma Tissue
Bank. The samples were chosen to give a representative
sampling of the full spectrum of neuroblastoma tumours
based on patient age, stage and N-myc copy number. We also
analysed clinical and tumour biological data on all
informative cases. Information available included patient
age, site of primary, stage, N-myc amplification, DNA index
and survival. One child (POG number 105760) with stage Ds,
diagnosed at age one month, was lost to follow up at 50
months and therefore was counted as censored at that time.
Polymerase chain reaction (PCR)
APC-specific primers were used to amplify a 133 bp region of
exon 11 of the APC gene using PCR (Meltzer et al., 1991).
The primer sequences used were as follows: 5'-GGC
TACATCTCCAAAAGTCAA-3' and 5'-GGACTACAGGC-
CATTGCAGAA-3'. The amplified segment contains a
restriction site polymorphism for RsaI at codon 486 of
APC. In the presence of the restriction site, digestion of the
PCR product with RsaI yields 85 bp and 48 bp fragments.
The PCR reaction contained 10 ng of genomic DNA and 1
unit of Taq polymerase (Promega, Madison, WI, USA) in a
50 jIl reaction volume. The first PCR cycle was run at a
denaturing temperature of 95°C for 105 s, an annealing
temperature of 59°C for 90 s and a polymerisation
temperature of 72°C for 45 s. The subsequent 28 cycles
were 20 s at 95°C, 45 s at 59°C and 30 s at 72°C. A control
tube that contained no genomic DNA was included in each
experiment.
The entire PCR product was digested overnight with 30
units of RsaI in a reaction volume of 60 ,ul. A PCR product
that was known to be homozygous for the RsaI site was used
to verify complete digestion each time a digestion reaction
was performed. The products of digestion were electrophor-
esed on a 7% native polyacrylamide gel containing 5%
glycerol at 150 V for 90 min. The gel was then stained with
ethidium bromide, destained and photographed using
Polaroid 55 negative/positive film. A laser densitometer
(LKB, Bromma, Sweden) and Gel Scan XL computer
program (Bromma, Sweden) were used to quantitate bands
on the Polaroid negatives. Our data readings were within the
linear capabilities of the equipment used.
The data obtained from the laser densitometer was
determined to be reproducible by repeated amplification
and cleavage of normal DNA from three heterozygotes
followed by electrophoresis and multiple scans of the
negatives (data not shown). In order to determine the linear
range of PCR amplification of the APC fragment, DNA
samples were amplified for 24, 26, 28, 30 and 32 cycles as
described above. The PCR product reached a plateau
between 30 and 32 PCR cycles (data not shown); therefore,
28 cycles were used to maximise PCR product, while
remaining in the linear range of amplification.
Theoretically, a mismatch of DNA strands in the final
cycle of the PCR reaction could lead to heterodimer
formation, that is, annealing of single-stranded DNA
containing an RsaI site to single-stranded DNA lacking the
site. In the presence of a heterodimer, RsaI would fail to cut
despite the presence of the restriction site motif on one DNA
strand, thus artifactually increasing the measured uncut allele.
We therefore performed in triplicate a mixing experiment in
which known amounts of genomic DNA homozygous for the
presence or absence of the RsaI site were mixed before PCR
amplification. These samples were then analysed as described
previously. The results showed that there was no heterodimer
formation, since the percentage of cut and uncut alleles after
PCR was the same as the percentage of each template added
to the PCR reaction (data not shown). These results
confirmed those of a similar mixing experiment (Meltzer et
al., 1991).
Normal DNA from patients' blood was PCR amplified,
digested, electrophoresed, photographed and scanned using a
laser densitometer. Patients whose normal DNA was
informative were studied further by comparing their normal
and tumour DNA. To determine which tumours showed
allelic imbalance, we used a combination of visual inspection
of the polyacrylamide gel, analysis of the allele index ratio
(described below) and three types of statistical cluster
analyses of the data obtained from scanning the gel (SAS
Institute, 1989). Estimates of survival curves were produced
using the method of Kaplan- and Meier (Kaplan and Meier,
1958). Standard errors of these estimates were obtained by
Peto's formula (Peto et al., 1977). Survival curves were
compared using the two-sided log-rank test (Mantel, 1968).
Other Sq loci
In cases showing Al involving the APC gene, loci D5S471
(5q23), D5S484 (5ql5) and D5S623 (5pl2) were also
amplified using primers and protocols from Research
Genetics (Huntsville, AL, USA). Thus, PCR amplification
on both telomeric and centromeric sides of APC, as well as
on the short arm of chromosome 5, were performed.
Allele index ratio
The allele index ratio was calculated by dividing the
densitometer reading of the uncut allele by the sum of the
two cut alleles. In normal DNA from heterozygotes, in which
both alleles were present in equal amounts, the mean allele
index ratio was 1.06+0.10 in 24 samples scanned. Tumours
that showed apparent allelic imbalance were PCR amplified
and analysed independently at least three times.
Fluorescence in situ hybridisation (FISH)
Purified DNA from a genomic clone representing the APC
locus was labelled with digoxigenin dUTP by nick translation.
Labelled probe was combined with sheared human DNA and
hybridised to touch preps made from neuroblastoma cells in a
solution containing 50% formamide, 10% dextran sulphate
and 2 x saline sodium citrate (SSC). Specific hybridisation
signals were detected by incubating the hybridised slides in
fluorescein-conjugated anti-digoxigenin antibodies.
Results
We studied 42 paired samples of normal and neuroblastoma
tumour DNAs for LOH of chromosome 5q at the APC gene
locus. Informative samples, heterozygous for the RsaI
restriction site, exhibited three distinct bands: 133 bp from
the uncut allele, and 85 bp and 48 bp from the cut allele.
Uninformative samples contained either two bands, 85 bp
and 48 bp in length, or a single band of 133 bp depending on
the presence or absence of the RsaI site respectively. Of the
42 samples, 24 (57%) were informative for the RsaI
restriction site.
Among the 24 informative samples, we observed an
imbalance of the two alleles, rather than complete loss of
heterozygosity. To determine quantitatively which tumour
DNAs exhibited allelic imbalance (AI), an allele index ratio
(AIR) was calculated (see Materials and methods), with the
results shown in Table I. In each case, the AIR was
approximately 1.0 for the normal DNA samples (data not
shown), but varied widely for the tumour samples. A
histogram showing the frequency distribution of the AIR in
normal and tumour samples is presented in Figure 1. In theAllelic imbalance in neuroblastoma
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Table I Clinical and molecular biological characteristics of tumours
Solo1p/e
numhber
Allelic ind1fex
JUltio
N-myc
n1u1m1be)
A. Patients exhibiting allelic imbalance of chromosome Sq
20 0.69 1
150 1.69 1
254 0.68 1
287 1.76 1
368 1.53 1
539 1.99 1
556 1.74 1
580 0.69 1
897 0.69 1
B. PaLtients not exhibiting allelic imbalance of chromosome 5q
13 1.13 NA A 93 (A)
34 0.98 2t)() 1.00 C 17 (D)
35 0.99 10 1.77 C 10 (D)
326 0.98 5) 1.19 D 0.2 (D)
353 1.09 1 1.30 C 4 (A)
594 1.04 1 1.00 Ds 33 (A)
649 1.08 15t) 1.00 C 21 (D)
651 1.01 1 1.09 D 28 (D)
661 0.96 1 NA C 18 (A)
691 0.92 1 1.23 B 26 (A)
701 1.16 1 1.22 Ds 23 (A)
714 1.21 1 1.90 Ds I (D)
747 0.97 75 1.00 D 125 (A)
759 1.03 1 1.86 A 25 (A)
767 1.31 NDb 1.00 D 6 (D)
"ND, not determined; NA, not available. "A, alive; L, lost to follow up; D, dead.
a
12
10 _
8
6
4
2
0
0.40-0.49 0.70-0.79 1.00-1.09 1.30-1.39 1.60-1.69 1.90-1.99
b
10
9
8
7
6
5
4
3
2
0
0.40-0.49 0.70-0.79 1.00-1.09 1.30-1.39 1.60-1.69 1.90-1.99
Figure 1 Frequency distribution of the allele index (ratio of
uncut cut allele) in normal (a) and tumour (b) samples.
tumour samples, there were three distinct groups: one had an
AIR of approximately 1.0, which was within the normal
range; the second group had an AIR of greater than 1.5,
indicating reduction of the cut allele; and the third group had
an AIR of less than 0.7, indicating reduction of the uncut
allele. Nine of the 24 (37.5%) informative tumour DNAs
exhibited allelic imbalance of chromosome Sq. Allelic
N T N T
133 bp-+
85 bp --
48 bp-+
1 2 3 4
Figure 2 Allelic imbalance at the APC locus. The position of the
band from the uncut allele (133 bp) and two bands from the cut
allele (85 and 48 bp) are indicated by arrows. Normal and tumour
DNA from the same patient are displayed side by side. DNA
from blood and the corresponding tumour DNA from patient 691
after amplification and R.saI digestion are shown in lanes 1 and 2
respectively. In this patient, there was an equal proportion of
uncut (upper 133bp band) to cut (lower bands 85 and 48bp)
alleles following digestion, therefore no allelic imbalance was
present. Lanes 3 and 4 show DNA from the blood and tumour,
respectively, of patient 539 exhibiting allelic imbalance of the cut
allele.
imbalance was approximately equally distributed between
the two alleles, with five of nine (55%) showing loss of the
cut allele and four of nine (45%) showing loss of the uncut
allele. Representative DNA samples from two patients are
shown in in Figure 2.
Clinical data were available for each of the patients we
analysed (Table I). This incuded age at diagnosis, site of
Foll/oot lo)
lilile (nonoolh.s)"
DNA
ijae -x
1.33
1.19
NA6
1.46
NA
1.47
1.55
1.20
1.29
Clinlical
Slage
Ds
C
B
C
A
C
C
A
A
51
69
51
54
46
35
30
33
12
(L)
(A)
(A)
(A)
(A)
(A)
(A)
(A)
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primary tumour, clinical stage, N-myc copy number, DNA
ploidy, follow-up interval and survival. Using Wilcoxon's
rank sum test for age and Fisher's exact test to compare
characteristics of those patients with and without Al with
respect to these parameters, except for survival, we
determined that all two-sided P-values exceeded 0.10 (data
not shown). Because of the small sample sizes, we cannot
exclude the possibility that these groups actually do differ on
some of these characteristics. The status of chromosome lp
was unavailable for the majority of patients.
Among the patients exhibiting Al, there were no POG
stage D patients (Hayes et al., 1983; Hayes and Smith, 1989).
In contrast, there were four stage D patients among the 15
patients lacking Al, suggesting a possible association between
the presence of Al and less severe disease. In fact, all nine
patients are alive after a median follow-up period of 46
months, while seven (47%) of those without Al have died.
From the Kaplan-Meier lifetime probability curves, three-
year survival of patients without A! of 5q was estimated to
be 49% (data not shown). The improved survival associated
with Al of 5q was statistically significant (P=0.018).
To determine the background rate of allelic imbalance, we
examined the loci of two additional tumour-suppressor genes,
p53 on chromosome 17 and DCC (deleted in colorectal
cancer) on chromosome 18 (Fearon et al., 1990) (Table II).
DNA from the same 42 patients was amplified by PCR using
primers specific for a variable number of tandem repeats
(VNTR) within p53 or primers specific for a polymorphic site
in the DCC gene, and the products were analysed. For p53,
26 cases were informative, of which three exhibited Al
(11.5%). One of them (patient 150) also exhibited Al at the
APC locus, one (patient 606) was not informative at APC
and the third (patient 701) did not exhibit Al on chromosome
5q. One additional patient (patient 767) exhibited complete
loss of one allele, demonstrating that our PCR-based
technique can distinguish between LOH and Al. Of the 27
informative cases for the DCC locus, only one (3.7%)
exhibited allelic imbalance; this case was not informative at
the APC locus.
Since the cells or nuclei from tumours were not sorted or
otherwise purified, contamination of tumour tissue with
normal tissue may have contributed to the fact that we
observed Al rather than LOH. To investigate this possibility,
nuclei from tumour tissue of patient 254 were flow
cytometrically sorted, then re-examined by PCR after
separation of hyperdiploid nuclei from normal, diploid
Table II Allelic imbalance on chromosomes 17 and 18
Sample N-myc DNA Clinical Follow-up
Chromosome number number index stage time (months)' APC status
17 150 1 1.19 C 69 (A) Al
606 1 1.82 D 29 (D) NI
701 1 1.22 Ds 23 (A) Negative
18 675 1 1.34 D 15(A) NI
aA, alive; L, lost to follow-up; D, dead. NI, not informative.
Figure 3 FISH analysis of the APC locus.Allelic imbalance in neuroblastoma
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nuclei. The Al of DNA from hyperdiploid nuclei was
unchanged (i.e., still imbalanced) after sorting, while the Al
of DNA from the diploid nuclei was in the normal range
(data not shown).
In six of the cases exhibiting Al, we examined markers
D5S471 (5q23), D5S484 (5q15) and D5S623 (5pl2). Where
results were informative, Al was also seen at these loci (data
not shown).
Finally, to determine whether the Al we observed resulted
from an extra copy of part or all of chromosome 5, FISH
was performed on tumour tissue from patient 254, the only
patient for whom tissue was available. The probe was a
cosmid containing the genomic APC gene. Analysis of this
experiment revealed that the cells contained two, three, four
or six copies of the APC gene per cell (Figure 3). Of 200 cells
analysed, 43% exhibited two copies, 26% exhibited three
copies, 22% exhibited four copies and 9% exhibited six
copies per cell. No single chromosome contained more than
one copy of the APC gene, suggesting that endoreduplication
of part of chromosome 5 had not occurred in this patient.
Since all cells contained at least two copies of APC, it is
unlikely that a deletion occurred. The presence of three, four
or six copies is consistent with hyperdiploidy, although the
DNA index for this patient is not known.
Discussion
We have shown that Al involving APC and other loci on
chromosome 5 occurs in 37.5% of neuroblastomas. Since Al
occurred in only 11.5% of informative cases at the p53 locus
and 3.7% ofinformative cases at the DCC locus in our study,
as well as at comparably low rates for other loci in other
studies (Brodeur et al., 1977; Suzuki et al., 1989; Srivatsan et
al., 1991; Fong et al., 1992), our data for chromosome 5 are
well above background for neuroblastomas. These data imply
that the entire chromosome 5 was involved in the allelic
imbalance we initially observed at the APC locus. Interest-
ingly, Al on chromosome 5 locus tends to occur in a subset
of neuroblastoma tumours in which the N-myc gene is not
amplified, the DNA index is greater than 1.00 and survival is
excellent.
Although the detection of Al was consistent and
reproducible, we did not observe complete loss of one allele.
There are several possible explanations for this observation: (1)
Contamination of tumour tissue with normal diploid tissue
may have occurred, since the nuclei were not sorted. This is
unlikely because, in tumour tissue of patient 254, DNA from
hyperdiploid nuclei still exhibited the same AIR as the unsorted
sample, while DNA from diploid nuclei did not show allelic
imbalance; (2) The tumour cell preparations may have included
a mixture of some tumour cells retaining and some lacking
chromosome 5. This could have been due to polyclonality
within the tumour or to the continued progression of
neuroblastoma, with Al of chromosome 5 constituting a late
event; (3) A likely possibility is that we may have been
observing endoreduplication of one homologue of chromo-
some 5, consistent with the fact that all of the cases exhibiting
Al for whom data were available were hyperdiploid. This
hypothesis is supported by FISH analysis oftumour tissue from
one patient exhibiting Al, in which there were two, three, four,
or six copies of the APC gene.
The Al we observed was widespread and involved multiple
loci on both arms of chromosome 5, suggesting reduplication
of the entire chromosome or large portions of it.
Endoreduplication would lead to an apparent increase in
either the cut or uncut allele in tumour DNA compared with
normal DNA, as we observed. Indeed, an extra chromosome
5 has been noted to occur in several neuroblastoma
karyotypes (Kaneko et al., 1987; Hayashi et al., 1989; Look
et al., 1991).
The presence of additional alleles of APC or another
gene(s) on chromosome 5 may affect tumorigenesis and
tumour behaviour. In other studies, APC copy number was
found to influence survival (Shimada and Masayuki, 1994).
An intriguing possibility in neuroblastoma is that additional
wild-type APC alleles present in tumour cells may have
suppressed their growth rate and/or tumorigenicity via a
dominant negative or 'threshold' effect. Precedent exists for
the dominant negative phenomenon in the case of p53, in
which introduction of a single copy of the wild-type gene into
osteosarcoma cells containing an endogenous mutated p53
gene suppressed the tumorigenicity of these cells and slowed
their growth rate (Chen et al., 1990). Similarly, introduction
of one copy of the p53 gene into a human lung carcinoma cell
line containing two normal p53 alleles also caused a
decreased growth rate and a decreased proportion of S-
phase cells (Noble et al., 1992). An alternative theory of
tumour-suppressor gene inactivation is the 'threshold
hypothesis', which holds that a critical amount of the gene
product is necessary for proper gene function. This theory is
supported by studies of melanoma cells, in which the degree
of growth suppression was proportional to the number of
copies of chromosome 6 that were introduced into cells
(Trent et al., 1990; Robertson et al., 1996). By analogy, extra
copies of chromosome 5 may confer growth-suppressive
effects on neuroblastoma cells and an advantage to
patients, consistent with the favourable prognosis we
observed for 5q allelic imbalance and already associated
with hyperdiploidy in neuroblastoma.
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